"post-embolisation syndrome: occurs in 90% of patients"
"Ia: homogeneous accumulation of iodised oil within the entire tumour and in the surrounding area - this type of accumulation indicates a good response to treatment"
"Ib: homogeneous accumulation of iodised oil within the entire tumour without accumulation in the surrounding area"
"type II: irregular accumulation with filling defect(s) - this pattern represents suboptimal response"
"type III: faint accumulation"
"type IV: no accumulation"
"type II: irregular accumulation with filling defect(s) - this pattern represents suboptimal response"
"Transcatheter arterial embolisation (TAE), also known as bland embolisation (i.e. without a chemotherapy agent added), is an alternative treatment option, and there is evidence that its efficacy is comparable to TACE."
"large burden of extra-hepatic metastases"
"In conventional TACE, administration of the chemotherapy agent is followed by mechanical embolisation, typically with gelfoam or PVA particles. In DEB-TACE, 100-300 micron drug-eluting beads are used instead 17."
"While there is no standardised method of assessing treatment response, the modified RECIST (mRECIST) criteria and the European Association for the Study of the Liver (EASL) criteria are typically used. Treatment response is classified as either complete response, partial response, stable disease, or progressive disease 14."
"While there is no standardised method of assessing treatment response, the modified RECIST (mRECIST) criteria and the European Association for the Study of the Liver (EASL) criteria are typically used. Treatment response is classified as either complete response, partial response, stable disease, or progressive disease 14."
"In the setting of a partial response, TACE may be repeated multiple times, but should ultimately be ceased if there is "untreatable progression", which is defined by significant tumour progression (e.g. massive liver involvement, extrahepatic spread, or vascular invasion), clinical or functional deterioration, or development of a contraindication 17."
Expected headings
"History"
"Response to treatment"
"Transcatheter arterial chemoembolisation (TACE), also known as transarterial chemoembolisation, is a minimally-invasive method of administering chemotherapy directly to a liver tumour via a catheter under digital subtraction angiography (DSA). The chemoembolic agent may be delivered as a mixture with Lipiodol (known as conventional TACE) or as an injection of drug-eluting beads (known as DEB-TACE)."
"There is wide variability in the type of chemotherapy agent and embolisation particles used, as well as the speed of injection 1. The most frequently used chemotherapy agent worldwide is doxorubicin 17. The chemotherapy agent is mixed with iodised oil, typically Lipiodol."
"In the setting of a partial response, TACE may be repeated multiple times, but should ultimately be ceased if there is "untreatable progression", which is defined by significant tumour progression (e.g. massive liver involvement, extrahepatic spread, or vascular invasion), clinical or functional deterioration, or development of a contraindication 17."